Frederick R. Aronson

Author

University of California, San Francisco

Also Known As

F Aronson, F R Aronson, F. R. ARONSON, F. R. Aronson, F.R. Aronson, Frederick Aronson, Frederick R. Aronson

Publications

1.6K

Citations

H-Index

Concepts

All Affiliations

University of California, San Francisco Tufts Medical Center Loyola University Medical Center Montefiore Medical Center City Of Hope National Medical Center

About

Frederick R. Aronson is an author at University of California, San Francisco specializing in medicine, immunology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	10	613
2	Health Sciences	2	2	112
3	Cell Biology	2	2	142
4	Allergy	1	1	42
5	Cellular Therapies	1	1	100

Frederick R. Aronson

Publications

1.5K

Citations

H-Index

Page 1

	Year	Citations
Interleukin-2 therapy in patients with metastatic malignant melanoma: a phase II study. David Parkinson, Jeff Abrams, Peter H. Wiernik, Journal of Clinical Oncology Interleukin-2 TherapyCancer ImmunosurveillanceMetastatic Malignant MelanomaMedicineMelanoma	1990	198
A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma. Geoffrey R. Weiss, Kim Margolin, Frederick R. Aronson, Journal of Clinical Oncology	1992	157
IL-4 inhibits IL-2 receptor expression and IL-2-dependent proliferation of human T cells. Olivia M. Martinez, Reta S. Gibbons, Marvin R. Garovoy, The Journal of Immunology	1990	150
IL-2 stimulates the production of IL-1 <i>alpha</i> and IL-1 <i>beta</i> by human peripheral blood mononuclear cells. Robert P. Numerof, Frederick R. Aronson, J W Mier The Journal of Immunology	1988	106
IL-2 rapidly induces natural killer cell adhesion to human endothelial cells. A potential mechanism for endothelial injury. Frederick R. Aronson, Peter Libby, Eugene P. Brandon, The Journal of Immunology Clinical ImmunologyAdded Il-2Cell TherapyImmunologyBlood Cell	1988	100
Metastatic malignant melanoma treated with combined bolus and continuous infusion interleukin-2 and lymphokine-activated killer cells. M H Bar, Mario Sznol, Michael B. Atkins, Journal of Clinical Oncology ImmunologyDermatologyImmunotherapyNatural Killer CellsCombined Bolus	1990	81
Outpatient subcutaneous interleukin-2 and interferon-alpha for metastatic renal cell cancer: five-year follow-up of the Cytokine Working Group Study. Janice P. Dutcher, Richard I. Fisher, Geoffrey R. Weiss, PubMed	1997	77
Randomized Trial of an Allogeneic Melanoma Lysate Vaccine With Low-Dose Interferon Alfa-2b Compared With High-Dose Interferon Alfa-2b for Resected Stage III Cutaneous Melanoma Malcolm S. Mitchell, Judith Abrams, John A. Thompson, Journal of Clinical Oncology	2007	76
Interleukin-2-based therapy for metastatic renal cell cancer: the Cytokine Working Group experience, 1989-1997. Janice P. Dutcher, Michael B. Atkins, Richard I. Fisher, PubMed	1997	69
Phase II Studies of Recombinant Human Interleukin-4 in Advanced Renal Cancer and Malignant Melanoma Kim Margolin, Frederick R. Aronson, Mario Sznol, Journal of Immunotherapy	1994	69

Page 1